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BACKGROUND: Stathmin1 is a microtubule-regulating protein that has an important role in the assembly and disassembly of the mitotic
spindle. The roles of stathmin1 in carcinogenesis of various cancers, including prostate and breast cancer, have been explored.
However, its expression and roles in gastric cancer have not yet been described.
METHODS:Stathmin1 expression in paraffin-embedded tissue sections from 226 patients was analysed by immunohistochemistry. Roles
of stathmin1 were studied using a specific small interfering RNA (siRNA).
RESULTS: The expression of stathmin1 was positively correlated with lymph node metastasis, TNM stages and vascular invasion, and
negatively with recurrence-free survival, in the diffuse type of gastric cancer. The median recurrence-free survival in patients with a
negative and positive expression of stathmin1 was 17.0 and 7.0 months, respectively (P¼0.009). When the expression of stathmin1
was knocked down using siRNA, the proliferation, migration and invasion of poorly differentiated gastric cancer cells in vitro were
significantly inhibited. Moreover, stathmin1 siRNA transfection significantly slowed the growth of xenografts in nude mice.
CONCLUSION: These results suggest that stathmin1 can be a good prognostic factor for recurrence-free survival rate and is a
therapeutic target in diffuse-type gastric cancer.
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Gastric cancer is the second most common cause of death from
cancer in the world (Yuasa, 2003). The 5-year survival rate remains
poor for this type of cancer (Wu et al, 1996, 1997; Lin et al, 1999).
Only two survival-influencing factors, the depth of invasion and
the presence of regional lymph node involvement, are commonly
used in prognosis (Wu et al, 1996, 1997; Lin et al, 1999). Compared
with other more extensively investigated cancers, such as breast,
prostate and colon carcinomas, the molecular mechanisms
involved in the transformation and progression of gastric cancer
are poorly characterised. The histology of gastric carcinomas is
conventionally classified into differentiated and undifferentiated
types. The intestinal type is a well-differentiated tumour charac-
terised by cohesive neoplastic cells forming gland-like tubular
structures, and the diffuse type is a poorly differentiated tumour
resulting in individual cells infiltrating and thickening the stomach
wall (Vogiatzi et al, 2007). The former is frequently accompanied
by liver metastasis, whereas the latter is frequently associated with
peritoneal dissemination (Vogiatzi et al, 2007).
Stathmin is one of the microtubule-regulating proteins that have
critically important roles in the assembly and disassembly of the
mitotic spindle (Belmont and Mitchison, 1996; Marklund et al,
1996; Mistry et al, 1998; Mistry and Atweh, 2001, 2006). The
stathmin protein family contains stathmin1 (STMN1, oncoprotein-
18/Op18, metablastin), stathmin-like2 (STMN2, superior cervical
ganglion-10 protein), stathmin-like3 (STMN3, superior cervical
ganglion-10-like protein) and stathmin-like4 (STMN4, RaB–GAP-
related protein 3) (Gavet et al, 1998; Singer et al, 2007). Stathmin1
is highly expressed in a wide variety of human cancers, including
leukaemia, breast, prostate and lung cancer, and provides an
attractive target for cancer therapy (Melhem et al, 1991; Friedrich
et al, 1995; Brattsand, 2000; Chen et al, 2003). Its expression in
cancer cells has been associated with their proliferation and
metastasis (Mistry and Atweh, 2006; Singer et al, 2007). Depending
on its phosphorylation state, which is mediated by p34cdc2 kinase,
mitogen-activated protein kinase and other kinases, stathmin1 can
regulate cell cycle through modulation of the mitotic spindle
(Marklund et al, 1993, 1996; Luo et al, 1994; Larsson et al, 1995;
Horwitz et al, 1997; Mistry and Atweh, 2006). Interestingly, when
biopsy specimens from human prostate cancers were immunos-
tained with an anti-stathmin1 antibody, immunoreactivity was
seen in poorly differentiated tumours but not in hyperplastic
prostate or highly differentiated tumours (Friedrich et al, 1995;
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sMistry and Atweh, 2006). More importantly, the level of stathmin
expression correlated with the malignant behaviour of prostate
cancer (Friedrich et al, 1995; Mistry and Atweh, 2006). Hence, it
was hypothesised that the level of expression of stathmin may
serve as a prognostic marker in prostate cancer.
The expression and possible roles of stathmin1 in stomach
cancers have never been investigated. To reveal possible prog-
nostic values and pathological roles of stathmin1 in gastric cancer,
we examined the expression of stathmin1. We also knocked down
stathmin1 expression in gastric cancer cells. We found that the
expression of stathmin1 was positively correlated with lymph node
metastasis, TNM stages and vascular invasion, and negatively with
recurrence-free survival, in the diffuse type of gastric cancer.
Moreover, knockdown of stathmin1 significantly reduced
proliferation and migration of gastric cancer cells.
MATERIALS AND METHODS
Tissue specimens
Tissue samples from 226 unrelated Korean patients with primary
gastric cancer, who were treated at Pusan National University
Hospital, were obtained at the time of surgical resection between
1994 and 2003. Tumours and patient-matched normal epithelium
were obtained at the time of surgical resection after the patients’
informed consent was obtained under a protocol reviewed and
approved by the institutional review board of Pusan National
University Hospital. The tissues were fixed in 10% buffered
formaldehyde solution for pathological diagnosis and immuno-
histochemical staining. Histopathological diagnosis of each
neoplastic tissue was performed according to the World Health
Organization criteria by the Department of Pathology, Pusan
National University Hospital. Clinicopathological staging was
determined by the TNM classification. All patients had gastric
cancer that was confirmed histologically, and tumour samples
were checked to ensure that tumour tissue was present in more
than 80% of the specimens. Follow-up data were collected until
December 2008 or until the patient’s death, and the occurrence of
metastasis and/or local recurrence was recorded.
Immunohistochemistry
Immunohistochemical staining with rabbit anti-human stathmin1
polyclonal antibody (Cell Signaling Technology, Danvers, MA,
USA, 1:50) and with rabbit anti-Ki-67 polyclonal antibody
(Novocastra, Newcastle, UK, 1:200) was performed on 4-mm
sections of paraffin-embedded specimens. Briefly, after deparaffi-
nation and hydration, the slides were incubated in 0.3% H2O2 for
30min to block endogenous peroxidase, after which the sections
were blocked for 1h at room temperature with 10% blocking
serum in phosphate-buffered saline (PBS) before reacting over-
night with anti-stathmin1 antibody at 41C in a moist chamber. For
Ki-67 immunostaining, antigen retrieval was performed (boiling
for 20min) in 10mM citrate buffer (pH 6.0). After incubation with
the primary antibody, the specimens were washed three times in
PBS and treated with secondary antibody at room temperature for
2h. After washing three times in PBS, the specimens were treated
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Figure 1 Immunohistochemical staining of stathmin1 in oral and gastric
cancer sections. Anti-stathmin1 antibody was used for immunohisto-
chemical staining in human oral and gastric cancer tissues as described
in ‘Materials and Methods’ section. The invading oral cancer cells were
positive for stathmin1 protein in the cytoplasm. The normal gastric mucosal
cells were either negative or very weakly positive for stathmin1 protein in
the cytoplasm. The invading gastric cancer cells were positive for stathmin1
protein. Scale bar, 200mm.
Table 1 Correlation between the expression of stathmin1 and clinical
classification in gastric cancer
Immunoreactivity case No. (%)
Clinical classification Total Negative Positive P-value*
Age at surgery (years) 0.202
o60 120 60 (50.0) 60 (50.0)
60p, o70 68 25 (36.7) 43 (63.3)
70p 38 16 (42.1) 22 (57.9)
Gender (diffuse type) 0.628
Male 43 31 (72.1) 12 (27.9)
Female 51 39 (76.5) 12 (23.5)
Gender (intestinal type) 0.464
Male 105 24 (22.9) 81 (77.1)
Female 27 8 (29.6) 19 (70.4)
N stages (diffuse type) 0.008
N0BN1 70 57 (81.4) 13 (18.6)
N2–N3 24 13 (54.2) 11 (45.8)
N stages (intestinal type) 1.000
N0BN1 116 27 (23.3) 89 (76.7)
N2–N3 16 4 (25.0) 12 (75.0)
TNM stage (diffuse type) 0.005
1B2 58 49 (84.5) 9 (15.5)
3B4 36 21 (58.3) 15 (41.7)
TNM stage (intestinal type) 0.946
1B2 107 25 (23.4) 82 (76.6)
3B4 25 6 (24.0) 19 (76.0)
Vascular invasion (diffuse type) 0.006
Negative 61 51 (83.6) 10 (16.4)
Positive 33 19 (57.6) 14 (42.4)
Vascular invasion (intestinal type) 0.634
Negative 98 22 (22.4) 76 (77.6)
Positive 34 9 (26.5) 25 (73.5)
Abbreviation: TNM¼The tumour-node-metastasis staging system. *Po0.05 was
defined as significant, Fisher’s exact test.
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swith ABC reagent (Dako, Carpinteria, CA, USA), followed by
colour development in 3,30-diaminobenzidine tetrahydrochloride
(Dako). Finally, the slides were lightly counterstained with
haematoxylin, dehydrated with ethanol, cleaned with xylene and
mounted. As a negative control, duplicate sections were immu-
nostained without exposure to primary antibodies. To quantify the
stathmin1 protein expression, the mean percentage of positive
tumour cells was determined by scoring at least 1000 tumour cells
of at least five random fields at  400 magnification in each
section. The intensity of tumour cell staining was deter-
mined relative to that observed in adjacent endothelial cells (0,
1, 2 and 3 for negative, weak, moderate and strong). The
percentage of positive tumour cells and staining intensity were
then multiplied to produce a stathmin1 immunohistochemical
staining score. Cases with a stathmin1 score greater than 10 were
defined as positive. For Ki-67 immunohistochemistry, the number
of positive tumour cells was counted in 10 representative visual
fields of each xenograft. Samples were scored by two independent
pathologists, neither of whom had knowledge or information
pertaining to the patients’ clinical status. Statistical significance
was evaluated by Fisher’s exact test, the Mann–Whitney U-test or
Student’s t-test. Po0.05 was considered significant.
Cell culture
The gastric cancer-derived cell lines used in this study were SNU16
and SNU638 cells. Gastric cancer-derived cell lines were grown in
RPMI 1640 medium supplemented with 10% fetal bovine serum
(FBS) and 50Uml
 1 penicillin and streptomycin (Sigma, St Louis,
MO, USA). The cells were grown at 371C in a humidified
atmosphere containing 5% CO2. Stock cultures of each cell line
were routinely sub-cultured at least once a week and the medium
was changed every 2–3 days.
siRNA and transfection
Stathmin1 small interfering RNA (siRNA) and scrambled (SCR)
siRNA were purchased from Dharmacon RNA Technologies
(ON-TARGET plus, Lafayette, IN, USA) and introduced into cell
lines with DharmaFECT reagents according to the manufacturer’s
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Figure 2 Correlationship between the stathmin1 expression level and clinicopathological characteristics. Data of stathmin-positive patients with diffuse-
type gastric cancer are presented. (A) The state of stathmin1 protein expression in patients with lymph node metastasis in diffuse type gastric cancer
(n¼17) and in patients without metastasis (n¼7). Stathmin1 protein expression in patients with lymph node metastasis is significantly higher than in patients
without lymph node metastasis (*Po0.05, Mann–Whitney U-test). (B) The state of stathmin1 protein expression in patients with early stages (I and II) of
diffuse type gastric cancer (n¼9) and patients with advanced stages (III and IV) of diffuse-type gastric cancer (n¼15). Stathmin1 protein expression in
advanced stages is significantly higher than that in early stages (**Po0.01, Mann–Whitney U-test). (C) The state of stathmin1 protein expression in patients
with vascular invasion in diffuse-type gastric cancer (n¼14) and in patients without vascular invasion (n¼10). Stathmin1 expression in patients with vascular
invasion is significantly higher than in patients without vascular invasion (**Po0.01, Mann–Whitney U-test).
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sinstructions. Dharmacon ON-TARGET plus siRNA contained four
kinds of siRNA to target one gene. The sequences of stathmin1
siRNA are as following: 50-GAAAGACGCAAGUCCCAUG-30;5 0-UA
AAGAGAACCGAGAGGCA-30;5 0-GAAACGAGAGCACGAGAAA-30
and 50-GAAGAGAAACUGACCCACA-30.
Cell proliferation assay
Approximately 3.0 10
3 cells in 100ml of medium were plated in
96-well plates and allowed to attach for 24h; cells were then treated
with the indicated concentrations of SCR control and stathmin1
siRNA. After 24h, the medium was replaced with 5% FBS medium.
After 5 days, 10ml per well of cell proliferation reagent WST-1
(Roche, Mannheim, Germany) was added and cells were further
incubated for 2h at 371C, 5% CO2, in a humidified incubator.
Absorbance of each well at 450nm was determined using an
ELISA reader (TECAN, Mannedorf, Switzerland). The cell pro-
liferation curve was plotted using the absorbance at each time
point. Viability was determined in quintuplicate.
Cell migration assay
A modified Boyden chamber (Neuro Probe, Gaithersburg,
MD, USA) was used. The pore size of polycarbonate filters was
8.0mm. The bottom chamber of the transwell chamber was filled
with 30ml RPMI containing 10% FBS. At 2 days after trans-
fection with SCR or stathmin1-siRNA, cells were trypsinised. The
cells were then suspended at a density of 1 10
6 cells per ml
in 50ml of RPMI supplemented with 0.5% FBS and placed in
the upper chamber. The cells were incubated 2h at 371Ci n
5% CO2. After the upper side of the filter was scraped with
a cotton tip to eliminate cells that had not migrated through it,
the filter was removed and fixed in methanol before staining
with Diff Quik Solution (Sysmex, Kobe, Japan). The cell number
in 10 randomly chosen fields was determined using a light
microscope. Experiments were performed in triplicate and
repeated three times.
Matrigel invasion assay
At 1 day after transfection with SCR or stathmin1 siRNA, cells were
trypsinised. The cells were then suspended at a density of 5 10
4
cells per ml in 500ml of RPMI supplemented with 0.5% FBS and
mitomycin C (0.01mgml
 1, Sigma), added to 8-mm porous BioCoat
Matrigel chamber inserts (BD Biosciences, San Jose, CA, USA) and
placed in wells filled with 0.7ml of medium supplemented with
10% fetal calf serum as chemoattractant. After 2 days of
incubation, the upper side of the filter was scraped with a cotton
tip to eliminate cells that had not migrated through it. The invasive
ability of the cells was determined by counting the cells that had
migrated to the lower side of the filter with a microscope.
Experiments were performed in triplicate, and at least 10 fields
were counted in each experiment.
Western blotting
Total protein extracts were separated by 10–12% SDS–PAGE
(20–50mg per lane), and electro-transferred to polyvinylidene
fluoride membranes. Anti-stathmin1 (1:500, Cell Signaling
Technology) and anti-b-actin (1:1000, Abcam, Cambridge, UK)
antibodies were diluted in PBS/T (PBS/tween; 5% milk powder)
and incubated with the membranes at 41C overnight. The
appropriate secondary antibody was applied (1:2000, horseradish
peroxidase-conjugated anti-mouse and anti-rabbit) at room
temperature for 1h. Immunoreactive proteins were visualised by
enhanced chemiluminescence (Amersham Bioscience, Freiburg,
Germany).
RNA preparation, complementary DNA synthesis and
quantitative real-time PCR
Total RNA was isolated from SNU638 cell lysates using an RNeasy
Mini Kit (Qiagen, Hilden, Germany) according to the manufac-
turer’s instructions. Total RNA was then treated with DNase I in
the presence of anti-RNase (Ambion, Austin, TX, USA) to remove
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Figure 3 Kaplan–Meier curves for recurrence-free survival according to
stathmin1 overexpression in patients with gastric cancer ((A) diffuse
typeþintestinal type, Po0.05; (B) diffuse type only, Po0.01). When
stathmin1 overexpression was observed, the recurrence-free survival rate
decreased significantly, especially in patients with diffuse-type gastric cancer.
Table 2 Univariate and multivariate analysis of prognostic factors in the
diffuse type of gastric cancer patients for recurrence-free survival
Univariate
analysis
Multivariate analysis
P-value P-value RR (95% CI)
Age (years) 0.508 0.694 0.837 (0.345-2.033)
o60 (vs X60)
Gender 0.090 0.850 1.104 (0.395-3.088)
Male (vs female)
Lymph node metastatsis 0.010 0.230 0.488 (0.151-1.576)
N2+N3 (vs N0+N1)
TNM stage 0.024 0.349 0.576 (0.181-1.829)
StageIII+IV (vs stageII+I)
Stathmin1 expression 0.009 0.049 0.328 (0.108-0.996)
Positive (vs negative)
Abbreviations: CI¼confidence interval; RR¼relative risk; TNM¼The tumour-node-
metastasis staging system.
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sDNA contamination before complementary DNA synthesis. The
complementary DNA was synthesised with random primers
(Roche, Basel, Switzerland) and avian myeloblastosis virus reverse
transcriptase (Promega, Madison, WI, USA). Real-time PCR
(power SYBR Green, ABI, Warrington, UK) analysis was
performed using an ABI Prism 7500 Sequence Detector according
to the manufacturer’s protocol. Primer sequences were as follows:
for stathmin1, 50-CCCCTTTCCCCTCCAAAGAA-30 (forward),
50-TCGCAAACGTTCCAGTTTGG-30 (reverse); and for b-actin,
50-ATCATGTTTGAGACCTTCAA-30 (forward), 50-CATCTCTTGCT
CGAAGTCCA-30(reverse). Fold changes for the genes of interest
were calculated after normalisation with the endogenous control
b-actin and using the comparative threshold cycle (Ct) method. These
experiments were performed in triplicate and repeated in three
independent experiments.
Xenograft assay
The SNU638 cells were transfected with SCR or stathmin1 siRNA.
After 2 days, cells were collected by trypsinisation and washed twice
before injection. Cell vitality was 495% as determined by trypan
blue dye exclusion. Cells (2 10
6 cells in 100ml PBS) were injected
subcutaneously into nude mice. All injected mice formed tumours.
Tumour volumes were measured every week from week 3 to week 7
and calculated using the following formula: 0.5236 L1 (L2)
2,
where L1 is the long axis and L2 is the short axis of the tumour
(Qian et al, 2007). After 7 weeks, mice were killed. Tissues were fixed
in 10% buffered formaldehyde solution and paraffin blocks were
obtained. Procedures related to animal care were in accordance
with the guidelines of the ‘Guideline for the Welfare of Animals
in Experimental Neoplasia’(Workman et al, 1998). The Pusan
National University Institutional Animal Care and Use Committee
(PNUIACUC) approved the experimental procedures.
Terminal deoxynucleotidyl transferase dUTP nick
end-labelling assay
Apoptosis was evaluated using the terminal deoxynucleotidyl
transferase dUTP nick end-labelling assay. The terminal deoxy-
nucleotidyl transferase dUTP nick end-labelling assay was per-
formed using the In Situ Apoptosis Detection Kit (Chemicon,
Temecula, CA, USA) according to the manufacturer’s instructions.
Apoptotic cells were visualised under fluorescent microscope
(Olympus BX50, Tokyo, Japan). The number of apoptotic cells as a
percentage of the total number of cells was calculated on the basis
of data obtained from 10 random areas. Each experiment was
repeated four times.
Statistical analysis
Statistical comparison between two groups was performed using
the non-parametric Mann–Whitney U-test or Student’s t-test.
For comparison of more than three groups, we used one-way
analysis of variance, followed by Tukey’s multiple comparison.
P-values o0.05 were considered statistically significant. The
overall survival time was defined as the interval between the
date of treatment and the date of death or until the last objective
follow-up information was obtained. Recurrence-free survival
time was regarded as the time interval between tumour treat-
ment and detection of the first locoregional recurrence and/or
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Figure 4 Stathmin1 was specifically downregulated by stathmin1siRNA. Cells were transfected with scrambled siRNA or stathmin1 siRNA. (A) Two days
later, SNU638 and SNU16 cells were collected and stathmin1 protein levels were detected by western blotting. b-actin expression was monitored for
normalisation. (B) SNU638 cells were collected and stathmin1 mRNA levels were examined by real-time PCR. Values are expressed as the percentage of
control, which was defined as 100% (n¼6). Results were analysed by one-way ANOVA, followed by Tukey’s multiple comparison test. *Po0.01 vs control.
mRNA, messenger RNA; SCR, scrambled; siRNA, small interfering RNA.
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sdistant metastasis or the date of last follow-up, whichever occurred
first. Recurrence-free survival according to stathmin1 overexpres-
sion was constructed using the Kaplan–Meier method. Curves were
compared by the log-rank test at 95% significance. Multi-
variate analysis was carried out using the Cox regression method. A
P-value o0.05 was considered to be statistically significant. Data were
analysed using SPSS software, version 12.0 (SPSS, Chicago, IL, USA).
RESULTS
Immunohistochemical analysis of stathmin1
þ cells in
gastric cancer
To characterise stathmin1 expression in human gastric cancer,
we used archival paraffin-embedded tissue sections (total 226
patients) for immunohistochemistry. A rabbit anti-stathmin1
antibody (Cell Signaling Technology) was evaluated and then
recommended for both western blot and immunohistochemistry
by the manufacturer. To evaluate the anti-stathmin1 antibody
in our lab, we performed immunohistochemistry using oral
squamous cancer tissue. Stathmin1 was expressed in invading
oral cancer cells (Figure 1A), which was consistent with the
previous report (Kouzu et al, 2006). In normal gastric mucosa,
it was difficult to detect stathmin1 expression; however, we clearly
observed cytoplasmic expression of stathmin1 in gastric cancer
tissue and in metastatic gastric cancer cells (Figure 1). Stathmin1
was expressed in 25.5 and 76.5% of diffuse and intestinal types
of gastric cancer tissues, respectively. The correlation between
the clinicopathological characteristics of patients with gastric
cancer and the status of stathmin1 expression is summarised in
Table 1. Interestingly, in the diffuse type of gastric cancer,
stathmin1 expression was correlated with N staging (P¼0.008;
Table 1). The stathmin1 expression level was also significantly
higher in the gastric cancer group with lymph node metastasis
than in the group without lymph node metastasis (Mann–Whitney
U-test, P¼0.013, Figure 2). Moreover, stathmin1 expression
correlated with the TNM stage grading of the diffuse type of
gastric cancer (P¼0.005; Table 1). The stathmin1 expression
level was also significantly higher in the group with advanced
gastric cancer than in the group with early-stage cancer (Mann–
Whitney U-test, P¼0.002, Figure 2). Furthermore, stathmin1
expression correlated with vascular invasion in diffuse-type gastric
cancer (P¼0.006; Table 1). The stathmin1 expression level was
also significantly higher in the group with vascular invasion than
in the group without vascular invasion (Mann–Whitney U-test,
P¼0.003, Figure 2).
Prognostic significance of stathmin1 expression in gastric
cancer
To evaluate stathmin1 expression as a prognostic factor, we
performed survival analysis using the Kaplan–Meier method. The
overall survival curves in relation to stathmin1 expression were not
significant (data not shown). However, the recurrence-free survival
curves in relation to stathmin1 expression were significant
(P¼0.049, Figure 3). The mean recurrence-free survival was 25.1
months (median 17.0 months) in the stathmin1-negative group
and 17.4 months (median 11.0 months) in the stathmin1-positive
group. Interestingly, in the diffuse type of gastric cancer, the
relationship between stathmin1 expression and recurrence-free
survival was more significant (P¼0.009, Figure 3). The mean
recurrence-free survival was 25.9 months (median 17.0 months) in
the stathmin1-negative group and 9.0 months (median 7.0 months)
in the stathmin1-positive group. When we analysed the recur-
rence-free survival of the earlier case groups (stages 1–2) to avoid
the influence of stage deviation, the difference was still significant
(P¼0.042). Prognostic significance of stathmin1 expression in
the diffuse type of gastric cancer was further confirmed by
multivariate survival analysis (Table 2).
Roles of stathmin1 in gastric cancer cells
To examine the possible roles of stathmin1 in gastric cancer cells,
we knocked down the expression of stathmin1 using siRNA. Before
siRNA experiments, we confirmed stathmin1 expression in gastric
cancer cell lines by western blotting (data not shown). To confirm
the efficacy of stathmin1 siRNA, we performed real-time PCR and
western blotting (Figure 4). When SNU638 and SNU16 cells were
transfected with stathmin1 siRNA, the expression of stathmin1 was
almost completely abolished at the protein level (Figure 4A).
Moreover, the messenger RNA level was also significantly reduced
by siRNA (Figure 4B). To examine the role of stathmin1 in
proliferation, we conducted WST assays after the transfection of
stathmin1 siRNA. Stathmin1 siRNA significantly reduced the
proliferation of SNU638 and SNU16 cells compared with SCR
siRNA at 100nM (Figure 5A and B). We next examined the role of
stathmin1 in cancer cell migration. We observed a significant
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Figure 5 Effect of stathmin1 silencing on proliferation of gastric cancer
cells. SNU638 (A) or SNU16 (B) cells were transfected with SCR siRNA
or stathmin1 (STMN1) siRNA. After 5 days of incubation, cell proliferation
was evaluated in WST assay. Data are expressed as percentage change
(means±s.d.) compared with controls and represent four independent
experiments. (*Po0.05, **Po0.01 vs SCR siRNA, one-way ANOVA
followed by Tukey’s multiple comparison). ANOVA, one-way analysis of
variance; SCR, scrambled; siRNA, small interfering RNA.
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sdifference between cells transfected with SCR or stathmin1 siRNA
in the migration assay (Figure 6A). Moreover, cancer cell invasion
was also significantly reduced by stathmin1 siRNA in the Matrigel
invasion assay (Figure 6B).
To confirm this effect of stathmin1 siRNA in vivo,w e
subcutaneously inoculated nude mice with SNU638 cells trans-
fected with SCR or stathmin1 siRNA. We observed significantly
slower growth of cancer cells transfected with stathmin1 siRNA
than of cancer cells transfected with SCR siRNA (Figure 7). When
we examined the tumour tissues of xenografts, the expression of
stathmin1 was significantly reduced in the stathmin1 siRNA group
compared with the SCR group (Supplementary Figure 1). More-
over, proliferation was also reduced in the stathmin1 siRNA group
(Supplementary Figure 2). In contrast, apoptosis was significantly
increased in the stathmin1 siRNA group compared with the SCR
group (Supplementary Figure 3).
DISCUSSION
Stathmin1 is expressed in the more poorly differentiated types of
several cancer tissues. In prostate cancer, stathmin1 expression is
similar in Gleason patterns 3 and 4; however, a significant increase
in stathmin1 levels occurs in Gleason pattern 5. Similarly, greater
expression of stathmin1 was observed in androgen-independent
cancer cells than in androgen-dependent cancer cells (Friedrich
et al, 1995). In breast cancer, stathmin1 levels negatively correlated
with estrogen receptor expression and positively correlated with
a high fraction of aneuploid cells, proliferation, tumour size
and histopathological grade (Brattsand, 2000). In this study, we
characterised stathmin1 expression in gastric cancer. In normal
mucosa, stathmin1 was rarely detected. Interestingly, significant
association of stathmin1 expression with more advanced stages,
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Figure 6 Effect of stathmin1 silencing on the migration and invasion of gastric cancer cells. (A) Cell migration was evaluated in the Boyden migration assay
two days after SNU638 cells were transfected with scrambled (SCR) small interfering RNA (siRNA) or stathmin1 siRNA. (B) Cell invasion was evaluated in
the Matrigel invasion assay as described in the ‘Materials and Methods’ section. Data are expressed as percentage change (means±s.d.) compared with
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comparison). Representative microscopic images were presented in the upper panel of each assay graph. ANOVA, one-way analysis of variance; SCR,
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Figure 7 Effect of stathmin1 silencing on in vivo tumour growth.
(A) SNU638 cells were transfected with scrambled (SCR) small interfering
RNA (siRNA) or stathmin1 (STMN1) siRNA, and nude mice were
inoculated subcutaneously with 2 10
6 cells at two sites per mouse. The
tumour mass (xenograft) volume was measured every week from week
3 to week 7. Data are expressed as the means±s.d. and represent four
independent experiments. (*Po0.05, **Po0.01 vs SCR siRNA, one-way
analysis of variance (ANOVA) followed by Tukey’s multiple comparison)
(B) The tumour masses (xenograft) were dissected out 7 weeks later and
presented. ANOVA, one-way analysis of variance; SCR, scrambled; siRNA,
small interfering RNA.
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slymph node metastasis and vascular invasion was observed in the
diffuse type of gastric cancer. Stathmin1 was also detected in
invading gastric cancer cells. Moreover, the association of
stathmin1 expression with the recurrence-free survival rate was
more significant in the diffuse type of gastric cancer. Furthermore,
in this study, functional significance of stathmin1 was demon-
strated in SNU638 and SNU16 cells. These results suggest that
stathmin1 might be a good prognostic factor in the diffuse type of
gastric cancer.
Critical roles for stathmin1 in the proliferation of cancer cells,
such as prostate cancer and osteosarcoma cells, have been
demonstrated (Mistry and Atweh, 2006; Wang et al, 2007). In this
study, we show, to the best of our knowledge, for the first time
that stathmin1 regulates proliferation of poorly differentiated
gastric cancer cells. Two mechanisms for stathmin1 regulation of
microtubules and proliferation have been suggested (Rubin and
Atweh, 2004). Stathmin1 can bind two unpolymerised tubulin
heterodimers and form a ternary stathmin–tubulin complex. This
tubulin-sequestrating activity of stathmin prevents microtubule
growth by diminishing the intracellular pool of tubulin that is
available for polymerisation. The other mechanism of stathmin
regulation of proliferation is a catastrophe-promoting activity.
Stathmin binds tubulin heterodimers at the microtubule ends
and increases the rate of catastrophe through a GTP hydrolysis-
dependent mechanism.
The importance of stathmin1 in cell migration has been
demonstrated (Ozon et al, 2002; Jin et al, 2004; Giampietro et al,
2005). Stathmin1 downregulation in vivo in both mice and
Drosophila decreased the motility of proliferating neurons and
germ and border cells. Moreover, stathmin1 is overexpressed in
metastatic vs clinically localised prostate carcinomas, invasive
recurrent hepatocarcinomas, advanced mammary carcinomas and
recurrent/metastatic sarcomas. These results suggest that increased
stathmin1 expression and activity stimulates cancer cell migration
in vitro, in vivo and in human cancers. In this study, we examined
the possible roles of stathmin1 in the migration of gastric cancer
cells because it was expressed in invading gastric cancer cells.
In agreement with previous reports, we observed a significant
difference in the migration of SCR and stathmin1 siRNA-
transfected cells. Regulation of cancer cell migration by stathmin1
may explain the greater lymph node metastasis and poor prognosis
in gastric cancer patients with stathmin1 overexpression.
The effects of stathmin1 silencing on proliferation and migra-
tion of gastric cancer cells in this study were not complete,
although protein expression of stathmin1 was almost completely
abolished. This may be due to other microtubule integrity
modifiers, such as other stathmin family members (STMN2–4),
which may compensate for the lack of stathmin1 expression after
siRNA-mediated silencing.
In this study, we showed for the first time that stathmin can be
used as a good prognostic factor and therapeutic target in the
diffuse type of gastric cancer. In future studies, it needs to be
examined whether stathmin1 silencing can increase the respon-
siveness of gastric cancer cells to different anti-cancer drugs.
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